Fate Therapeutics (FATE) Payables (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Payables data on file, last reported at $3.3 million in Q1 2026.

• Quarterly Payables fell 21.79% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 21.79% YoY) and the FY2025 annual result came in at $2.7 million, down 71.64% from the prior year.
• Payables improved to $3.3 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $11.4 million in Q1 2022 to a low of $2.7 million in Q4 2025.
• A 5-year average of $6.5 million and a median of $6.3 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2024 — Payables surged 98.45% — and 2025, when it plunged 71.64%.
• Tracing FATE's Payables over 5 years: stood at $8.3 million in 2022, then slumped by 42.9% to $4.7 million in 2023, then soared by 98.45% to $9.4 million in 2024, then sank by 71.64% to $2.7 million in 2025, then advanced by 23.38% to $3.3 million in 2026.
• The last three Payables figures came in at $3.3 million (Q1 2026), $2.7 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.